PBL15 Antibody
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Schengen1 (sgn1), a receptor-like cytoplasmic kinase, exhibits strict polar localization to the outer plasma membrane of endodermal cells. It is essential for the proper positioning and formation of the centrally located CASP domain. [Schengen1] PMID: 27455051
Q&A
Generating FAQs for the PBL15 antibody requires synthesizing academic rigor with practical research troubleshooting. Below is a structured breakdown of questions reflecting both foundational and advanced research challenges, informed by antibody validation principles from peer-reviewed guidelines and experimental design best practices.
Advanced Research Questions
How to resolve contradictory data between PBL15 and alternative antibodies targeting the same protein?
-
Methodological answer:
-
Epitope mapping: Compare immunogen sequences (e.g., linear vs. conformational epitopes).
-
Technical variables: Audit fixation protocols (e.g., paraformaldehyde vs. methanol) and antigen retrieval methods.
-
Quantitative validation: Use siRNA knockdown followed by qPCR and antibody staining to correlate protein/mRNA levels.
-
What strategies mitigate batch-to-batch variability in PBL15 antibody performance?
-
Methodological answer:
-
Batch pre-testing: Compare new batches using standardized positive controls (e.g., reference cell lines).
-
Multiplex validation: Run parallel experiments with previous batches on the same blot or slide.
-
Public databases: Deposit validation data in repositories like Antibodypedia or CiteAb for community reference .
-
Data-Driven Insights
| Validation Parameter | Optimal Result | Common Pitfalls |
|---|---|---|
| Signal specificity (IHC) | No staining in knockout controls | Cross-reactivity with homologous proteins |
| Batch consistency (Western blot) | ≤20% variance in band intensity | Aggregation due to improper storage |
| Epitope integrity | Matches immunogen sequence (BLAST) | Post-translational modifications masking epitopes |
